{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:52:03Z","timestamp":1781880723850,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is an immune-mediated inflammatory demyelinating disease affecting the optic nerve and spinal cord. NMOSD frequently coexists with other autoimmune diseases. However, its concurrence with mixed connective tissue disease (MCTD) is rather rare and often overlooked. This study reports the first case in China of aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive NMOSD preceding MCTD with long-term follow-up. Between 2016 and 2024, the patient successively developed left lower limb numbness, hiccups, vomiting, facial numbness, Raynaud\u2019s phenomenon, finger swelling, digital sclerosis, and synovitis. Acute-phase management involved pulse steroid therapy, while remission maintenance utilized azathioprine, mycophenolate mofetil, rituximab, and inebilizumab for relapse prevention. This paper presents this case and reviews other cases of NMOSD combined with MCTD, aiming to contribute to the clinical understanding and management of this rare condition.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1644259","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:23:36Z","timestamp":1757481816000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and mixed connective tissue disease: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ziyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2012.06.013","article-title":"Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies","volume":"44","author":"Ratelade","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.008","article-title":"Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review","volume":"27","author":"Shahmohammadi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e30347","DOI":"10.1097\/MD.0000000000030347","article-title":"A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders","volume":"101","author":"Dong","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"103882","DOI":"10.1016\/j.msard.2022.103882","article-title":"The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients","volume":"63","author":"Pathomrattanapiban","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B7","doi-asserted-by":"publisher","first-page":"103352","DOI":"10.1016\/j.msard.2021.103352","article-title":"Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study","volume":"57","author":"Flanagan","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887041","article-title":"The first case report of preschool-onset SS\/SLE coexisting with NMOSD of Chinese origin","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1371515","article-title":"A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sj\u00f6gren\u2019s syndrome and pancytopenia treated with inebilizumab","volume":"15","author":"Li","year":"2024","journal-title":"Front Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e39687","DOI":"10.1016\/j.heliyon.2024.e39687","article-title":"Neuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318760994","article-title":"Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab","volume":"27","author":"Shidahara","year":"2018","journal-title":"Lupus"},{"key":"B12","article-title":"Devic\u2019s syndrome and mixed connective tissue disease: an unusual association","volume":"43","author":"Silva","year":"2018","journal-title":"Acta Reumatol Port"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e318262df28","article-title":"A rare case of mixed connective tissue disease complicated with neuromyelitis optica","volume":"18","author":"Parperis","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21037\/acr-23-48","article-title":"AQP4 antibody-seropositive neuromyelitis optica spectrum disorder in a patient with mixed connective tissue disease: a case report","volume":"9","author":"Polilli","year":"2025","journal-title":"AME Case Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11926-021-01000-2","article-title":"Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist","volume":"23","author":"Cruz","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.31083\/j.jin2302035","article-title":"Systemic connective tissue disease and neuromyelitis optica spectrum disorder coexistence: A systematic review and meta-analysis","volume":"23","author":"Esposito","year":"2024","journal-title":"J Integr Neurosci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/09612033231191180","article-title":"Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data","volume":"32","author":"Kopp","year":"2023","journal-title":"Lupus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319877255","article-title":"Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience","volume":"28","author":"Mart\u00edn-Nares","year":"2019","journal-title":"Lupus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000703","article-title":"Update on neuromyelitis optica spectrum disorder","volume":"31","author":"Holroyd","year":"2020","journal-title":"Curr Opin Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15983","article-title":"Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review","volume":"30","author":"Zara","year":"2023","journal-title":"Eur J Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16136","DOI":"10.1038\/s41598-019-52506-w","article-title":"A highly specific and sensitive nanoimmunosensor for the diagnosis of neuromyelitis optica spectrum disorders","volume":"9","author":"de Souza Moraes","year":"2019","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2024.2338593","article-title":"Evolution of diagnostic criteria and new insights into clinical testing in mixed connective tissue disease; anti-survival motor neuron complex antibody as a novel marker of severity of the disease","volume":"47","author":"Kubo","year":"2024","journal-title":"Immunol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/ITT.S390023","article-title":"Towards early diagnosis of mixed connective tissue disease: updated perspectives","volume":"12","author":"Ferrara","year":"2023","journal-title":"Immunotargets Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S464704","article-title":"Interstitial lung disease in patients with mixed connective tissue disease: A retrospective study","volume":"17","author":"Shan","year":"2024","journal-title":"Int J Gen Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03935-y","article-title":"Myelopathy associated with mixed connective tissue disease: clinical manifestation, diagnosis, treatment, and prognosis","volume":"40","author":"Hao","year":"2019","journal-title":"Neurol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.969762","article-title":"Comparative analysis of clinical and imaging data of first-attack neuromyelitis optica spectrum disorders with and without connective tissue disease","volume":"13","author":"Yao","year":"2022","journal-title":"Front Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12883-018-1182-5","article-title":"Neuromyelitis optica spectrum disorders with and without connective tissue disorders","volume":"18","author":"Yang","year":"2018","journal-title":"BMC Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1644259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:23:36Z","timestamp":1757481816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1644259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1644259"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1644259","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1644259"}}